Argonaut | The Natural Choice in Resources

Argonaut is a full service advisory, stockbroking & research and investment house with offices in Perth and Hong Kong. Argonaut is technically driven & focused on natural resource companies & businesses that service the metals, mining, energy and agri-business sectors. Argonaut has an established track record of creating significant wealth for clients.

Morning Notes

U.S. stocks fell slightly as health-care shares jumped and oil prices stabilized. The Dow Jones Industrial Average shed 13 points, or 0.1%, to 21397. The S&P 500 and Nasdaq Composite finished relatively flat. Health-care shares, the best-performing sector in the S&P 500 this week, extended gains as Senate Republicans unveiled their health-care bill. The bill faces an uncertain future with several Republican senators wavering on it, but its release was a key step for President Donald Trump's agenda, some said. The removal of uncertainty on the health bill's contents and few apparent negatives for hospital and health-care stocks were likely contributing to the sector's gains Thursday, said Timothy Anderson, managing director at brokerage MND Partners. Health-care shares rose 1.5% and the Nasdaq Biotechnology Index, which is up roughly 10% so far this week, gained 1.9% Thursday. Energy shares also rose after falling alongside oil prices in recent sessions. The U.S. gold price also gained overnight, jumping 0.3% to 1,250.00 US$/oz.

More >

Latest Research

Kibaran Resources (KNL) released a revised Bankable Feasibility Study (BFS) for its 100% owned Epanko Graphite project in Tanzania. The study outlines a 50% increase in production to 60ktpa graphite concentrate for a 15% increase in pre-production capex (US$88.9m vs the US$77.5m in the 2015 BFS). The project generates a 30% post-tax IRR and has an initial 18-year mine life. Epanko is differentiated from other potential graphite development projects by its high grade and its large flake size distribution. KNL is the only graphite developer to have the majority of its forecast production in binding offtake agreements with non-Chinese parties. The revised BFS is differentiated from other studies by the rigour of independent assessment to meet Tanzanian and international social and financial standards. The Company is also investigating downstream processing to produce battery grade spherical graphite, with a BFS expected Q3 CY17.

More >

Latest News

Argonaut has acted as Lead Manager to Botanix Pharmaceuticals Ltd (ASX: BOT) (“Botanix”) in its oversubscribed placement of A$7.4 million to new and existing institutional and sophisticated investors.

More >